Sunday, April 19, 2026 – Plus, expert-backed tips for protecting your bones.

Friday, April 17, 2026 – Saturday, April 18 - Injectable peptides are generating a lot of buzz online.

Friday, April 17, 2026 – FRIDAY, April 17, 2026 -- In many incretin-based interventions, reductions in muscle-related indices exceed prespecified benchmarks, according to a review published online April 17 in the Annals of Internal Medicine to coincide with the Internal...

Friday, April 17, 2026 – Saturday, April 18 - A new approach to weight loss research is challenging one of the biggest assumptions behind popular weight loss drugs: Are GLP-1s actually needed to achieve weight loss?

Friday, April 17, 2026 – FRIDAY, April 17, 2026 — A new approach to weight loss research is challenging one of the biggest assumptions behind popular weight loss drugs: Are GLP-1s actually needed to achieve weight loss?In a new study published April 15 in the journal M...

Friday, April 17, 2026 – Saturday, April 18 - While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given the shorter data collection time for Foundayo.

Friday, April 17, 2026 – Saturday, April 18 - (MedPage Today) -- Note that some links may require registration or subscription.
Another side effect of GLP-1 drugs? Anecdotal reports from doctors and patients suggest the blockbuster diabetes and weight-loss drugs may cause a type of emotional...

Friday, April 17, 2026 – Saturday, April 18 - In a new study exploring stigma associated with the use of GLP-1 drugs for weight loss, women who lost weight using GLP-1 medications were judged more harshly than those who lost weight through diet and exercise, with negative reactions driven largely by beliefs that medication-assisted weight loss is a "shortcut." The study also found higher levels of stigma when the women in sample scenarios were portrayed as white rather than Black.

Friday, April 17, 2026 – Friday, April 17 - While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review.

The analysis, shared as ...

Thursday, April 16, 2026 – Friday, April 17 - Wall Street met with satisfaction but not surprise Eli Lilly and Co.’s undeniably positive top-line results from the phase III Achieve-4 study testing the efficacy and safety of Foundayo (orforglipron) compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.